Pathogenic Variants in Are Associated With an Adverse Prognosis in Symptomatic Early-Onset Breast Cancer.

Purpose: Checkpoint kinase 2 () is frequently included in multigene panels. We describe the associated outcomes among carriers of pathogenic variants in young patients with symptomatic breast cancer.

Patients And Methods: Participants (N = 2,344) in the Prospective Outcomes in Sporadic Versus Hereditary Breast Cancer study had a diagnosis of primary invasive breast cancer at age ≤ 40 years.